BeiGene Ltd - ADR

-15.64 (-6.28%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)23.89B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$326.54 Million
Adjusted EPS-$3.33
See more estimates
10-Day MA$241.61
50-Day MA$288.14
200-Day MA$324.76
See more pivots

BeiGene Ltd - ADR Stock, NASDAQ:BGNE

No. 30 Science Park Road, Zhong-Guan-Cun Life Science Park, Beijing, Beijing 102206
Cayman Islands
Phone: +86.10.85148500
Number of Employees: 5300


BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.